5395232025-10-012025-12-315395232025-04-012025-12-315395232025-10-012025-12-31in-capmkt:OtherExpenses1Member5395232025-04-012025-12-31in-capmkt:OtherExpenses1Member5395232025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15395232025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-132026-01-23INRMillionsQuarterlyThird quarterSingle segmentThe Company is exclusively engaged in pharmaceutical business2026-02-1311:00:002026-02-1313:45:00Not applicable2025-10-012025-12-31UnauditedConsolidated37368200000143100000038799200000937770000032796000006980000072151000004210000009501000009146000000304593000008339900000-52790000078120000001769700000-493000000127670000006535300000000-50000006530300000235700000676600000063601960001701000006595411000170600000239100000253.1953.190053.1953.191) The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). <BR> <BR> 2) The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 February 2026 and subsequently approved by the Board of Directors at its meeting held on 13 February 2026. The auditors have issued an unmodified review report on the financial results for the quarter and nine months ended 31 December 2025. <BR> <BR> 3) Exceptional items include: <BR> <BR> 1) The Government of India notified the four Labour Codes which are effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed the incremental impact of these changes on the basis of the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. <BR> <BR> The incremental impact basis preliminary analysis of Rs. 527.9 million is classified and disclosed as an exceptional item in the results for the quarter and nine months ended 31 December 2025. The Group continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate financial impact on the basis of such developments as needed. <BR> <BR> <BR> 2) The Parent Company sold its Indore manufacturing facility in the quarter ended 30 June 2025 in accordance with the business transfer agreement entered with the buyer. The resulting gain amounting to Rs. 142.9 million had been classified and disclosed as an exceptional item in the results for the nine months ended 31 December 2025. <BR> <BR> 4) The Board of Directors at its meeting held on 13 February 2026 have declared an interim dividend of Rs. 43 (Rupees Forty Three only) per equity share (2150% on the face value of Rs. 2 each) for the financial year ending 31 March 2026. <BR> <BR> 5) The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment information has been made.2025-04-012025-12-31UnauditedConsolidated11108950000038328000001149223000002670450000011967300000-2228000002125010000010690000002763000000265122000009004330000024879000000-398600000244804000004980300000-15144000003465900000021014500000000-14000000210005000006852000002168570000020653411000347100000213441110003416000002391000002172.74172.7400172.74172.74Other Expenses9146000000Other Expenses26512200000Remeasurements of defined benefit plans-141200000-141200000Remeasurements of defined benefit plans-233700000-233700000-50800000-80300000Foreign currency translation difference of foreign operations326100000326100000Foreign currency translation difference of foreign operations83860000083860000000235700000685200000